Early, soft fracture callus that links fracture ends together is smooth muscle-like in nature. We aimed to determine if early fracture callus could be induced to contract and relax ex vivo by similar pathways to smooth muscle, that is, contraction via a 1 adrenergic receptor (a 1 AR) activation with phenylephrine (PE) and relaxation via b 2 adrenergic receptor (b 2 AR) stimulation with terbutaline. A sensitive force transducer quantified 7 day rat rib fracture callus responses in modified Krebs-Henseliet (KH) solutions. Unfractured ribs along with 7, 14, and 21 day fracture calluses were analyzed for both a 1 AR and b 2 AR gene expression using qPCR, whilst 7 day fracture callus was examined via immunohistochemistry for both a 1 AR and b 2 AR-immunoreactivity. In 7 day callus, PE (10 À6 M) significantly induced an increase in force that was greater than passive force generated in calcium-free KH (n ¼ 8, mean 51% increase, 95% CI: 26-76%). PE-induced contractions in calluses were attenuated by the a 1 AR antagonist, prazosin (10 À6 M; n ¼ 7, mean 5% increase, 95% CI: 2-11%). Terbutaline did not relax callus. Gene expression of a 1 ARs was constant throughout fracture healing; however, b 2 AR expression was down-regulated at 7 days compared to unfractured rib ( p < 0.01). Furthermore, osteoprogenitor cells of early fibrous callus displayed considerable a 1 AR-like immunoreactivity but not b 2 AR-like immunoreactivity. Here, we demonstrate for the first time that early fracture callus can be pharmacologically induced to contract. We propose that increased concentrations of a 1 AR agonists such as noradrenaline may tonically contract callus in vivo to promote osteogenesis. ß